Search clinical trials for: oxymorphone HCl

Total 2783 results

Endo Pharmaceuticals

Suspended

Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children

Chronic Pain | Postsurgical Pain

United States
Endo Pharmaceuticals

Completed

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Post Operative Pain

United States
Endo Pharmaceuticals

Terminated

Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Acute Pain | Post-Operative Pain

United States
Icahn School of Medicine at Mount Sinai
Endo Pharmaceuticals

Completed

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

Pain

United States
Endo Pharmaceuticals

Completed

Post-operative Efficacy and Safety Study

Post-operative Pain
Endo Pharmaceuticals

Completed

Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain

Pain | Chronic Disease
Member Companies of the Opioid PMR Consortium

Terminated

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

Opioid-Related Disorders | Drug Abuse | Opiate Addiction | Narcotic Abuse

United States
Endo Pharmaceuticals

Withdrawn

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

Chronic Pain
Endo Pharmaceuticals

Completed

Open Label Assessment of Long-Term Safety and Utility

Pain
Sandoz

Completed

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions

Pain
Icahn School of Medicine at Mount Sinai
Endo Pharmaceuticals

Unknown

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

Neuropathic Pain | Non-cancer Pain | Chronic Nociceptive Pain

United States
Endo Pharmaceuticals

Completed

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

Lower Back Pain | Cancers, Pain

United States
Endo Pharmaceuticals

Completed

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

Chronic Pain

United States
Endo Pharmaceuticals

Completed

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

Chronic Pain

United States
MedVadis Research Corporation

Completed

Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

Chronic Pain

United States
Endo Pharmaceuticals

Completed

Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.

Postoperative Pain

United States
Sandoz

Completed

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions

Pain
Endo Pharmaceuticals

Completed

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

Acute Pain

United States
University of Virginia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

Type 1 Diabetes

United States
Endo Pharmaceuticals

Completed

Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

Cancer | Chronic Pain | Neuropathic Pain
Endo Pharmaceuticals

Terminated

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

Chronic Pain

United States
Rabin Medical Center
Medtronic; GIF

Completed

An Open-label, Two-center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of Glycemic Control Using Hybrid-closed Loop vs. Advanced Hybrid Closed-loop in Young Subjects With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany, Israel
Rabin Medical Center

Completed

Comparison of Two Closed-Loop Strategies for Glucose Control in Type 1 Diabetes The DREMED Trail- 2

Type 1 Diabetes

Israel
New York State Psychiatric Institute
University of Kentucky

Completed

A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.

Opioid Use Disorder

United States
Endo Pharmaceuticals
Kendle Early Stage - Toronto

Completed

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

Healthy

Canada
Universidad Complutense de Madrid

Completed

One- Versus Two-Stage Aesthetic Crown Lengthening

Patients in Need of Surgical CL in the Anterior Maxillary Sextant for Restorative Purposes
University of Kansas Medical Center
National Cancer Institute (NCI)

Completed

Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer

Breast Cancer

United States
Acologix, Inc.

Unknown

A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch) (AC120-8231)

Uremic Pruritus
Daiichi Sankyo, Inc.

Terminated

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
BioCryst Pharmaceuticals

Completed

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL)

United States, Australia
Daiichi Sankyo Co., Ltd.

Completed

Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes

Type 2 Diabetes

Japan
Daiichi Sankyo Co., Ltd.

Completed

Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes (RAISE)

Type 2 Diabetes

China
Eli Lilly and Company

Completed

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Non-Small-Cell Lung Carcinoma

United States
Helsinn Therapeutics (U.S.), Inc

Completed

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

Non-Small Cell Lung Cancer | Cachexia

Poland, United States, Israel, Russian Federation, Hungary, Australia, United Kingdom
Helsinn Therapeutics (U.S.), Inc

Completed

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Non-Small Cell Lung Cancer | Cachexia

Poland, Ukraine, United States, Belgium, Spain, Belarus, Slovenia, Serbia, Canada, Russian Federation, Australia, Hungary, Germany, Czechia, France, Israel, Italy
University of Rochester
Endo Pharmaceuticals

Terminated

Lumbar Stenosis Outcomes Research II (LUSTORII)

Lumbar Spinal Stenosis

United States
VA Office of Research and Development
Helsinn Therapeutics (U.S.), Inc

Terminated

The Role of Ghrelin in Cancer Cachexia

Cancer Cachexia

United States
Helsinn Therapeutics (U.S.), Inc

Completed

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

Non-Small Cell Lung Cancer | Cachexia

United States, Poland, Ukraine, Belgium, Germany, Spain, Belarus, Slovenia, Serbia, Netherlands, Canada, Russian Federation, Hungary, Czechia, France, Italy
Eli Lilly and Company

Completed

Enzastaurin for Patients With Metastatic Colorectal Cancer

Colonic Neoplasms

Sweden, Denmark
Artax Biopharma Inc
Simbec Research

Completed

Potential Food Effect And Repeated Dosing of AX-024.HCl In Healthy Subjects

Healthy

United Kingdom
Helsinn Therapeutics (U.S.), Inc

Completed

Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

Cancer Cachexia

United States
Universal Enterprises

Unknown

Bioequivalence of Phenazopyridine HCl in Healthy Volunteers

Human Volunteers

Pakistan
Abide Therapeutics

Completed

Central Pain Study for ABX-1431

Multiple Sclerosis | Neuromyelitis Optica Spectrum Disorder | Transverse Myelitis | Longitudinally Extensive Transverse Myelitis

United Kingdom
Loyola University

Completed

CATHETER ANALGESIA TRIAL Phenazopyrdine vs. Placebo: a Randomized Controlled Trial (CATH)

Catheter-related Bladder Discomfort

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

Glioma | Astrocytoma | Oligodendroglioma

United States
Centre Hospitalier Sud Francilien

Recruiting

Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age With Type 1 Diabetes (BFHado)

Type1 Diabetes | Adolescents | Young Adults

France
Cortexyme Inc.

Completed

A Multiple Ascending Dose Study of COR388

Alzheimer Disease

United States
Dendreon

Completed

Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors

Solid Tumors

United States
Stealth BioTherapeutics Inc.

Not yet recruiting

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) (ReNEW)

Age-Related Macular Degeneration
Amicus Therapeutics

Approved for marketing

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Fabry Disease

United States, Australia

3

Subscribe